A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.

Scientists studied a new way to help with learning and behavior problems in Neurofibromatosis type 1 (NF1), a genetic condition that can cause autism-like symptoms and ADHD. Using mice with NF1, they found a way to boost levels of an important protein that's usually low in this condition. When they did this, the mice showed improvements in social learning and less impulsive behavior. This research suggests a potential new treatment approach for the developmental challenges seen in NF1.

This preclinical study investigated a novel therapeutic approach for neurodevelopmental symptoms in Neurofibromatosis type 1 (NF1), including autism spectrum disorder and ADHD. Researchers used genetically engineered mouse models to test whether preventing degradation of neurofibromin protein could improve symptoms. They identified FBXW11 as a protein that degrades neurofibromin and found that disrupting this protein increased neurofibromin levels. In male Nf1+/- mice, this intervention corrected social learning deficits and impulsive behaviors by suppressing Ras-ERK signaling pathways.

The study demonstrates that haploinsufficiency restoration through preventing protein degradation represents a potentially feasible therapeutic strategy for addressing neurodevelopmental manifestations of NF1.

This preclinical research identifies a novel therapeutic target for neurodevelopmental symptoms in NF1. The haploinsufficiency restoration approach could potentially inform future drug development for autism spectrum and ADHD symptoms in NF1 patients, though human studies are needed to establish safety and efficacy.

Study conducted only in mouse models; sample size not reported; effects only demonstrated in male mice; long-term safety and efficacy unknown; translation to human applications uncertain.

Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations of the NF1 tumor suppressor gene resulting in the loss of function of neurofibromin, a GTPase-activating protein (GAP) for Ras. While the malignant manifestations of NF1 are associated with loss of heterozygosity of the residual WT allele, the nonmalignant neurodevelopmental sequelae, including autism spectrum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD) are prevalent morbidities that occur in the setting of neurofibromin haploinsufficiency. We reasoned that augmenting endogenous levels of WT neurofibromin could serve as a potential therapeutic strategy to correct the neurodevelopmental manifestations of NF1. Here, we used a combination of genetic screening and genetically engineered murine models to identify a role for the F-box protein FBXW11 as a regulator of neurofibromin degradation.

Disruption of Fbxw11, through germline mutation or targeted genetic manipulation in the nucleus accumbens, increased neurofibromin levels, suppressed Ras-dependent ERK phosphorylation, and corrected social learning deficits and impulsive behaviors in male Nf1+/- mice. Our results demonstrate that preventing the degradation of neurofibromin is a feasible and effective approach to ameliorate the neurodevelopmental phenotypes in a haploinsufficient disease model.